04:13 PM EST, 11/03/2025 (MT Newswires) -- Vertex Pharmaceuticals ( VRTX ) reported fiscal Q3 non-GAAP net income late Monday of $4.80 per diluted share, up from $4.38 a year earlier. Analysts polled by FactSet expected earnings of $4.58. Revenue in the three months ended Sept. 30 rose to $3.08 billion from $2.77 billion a year earlier. Analysts expected $3.06...

Overview * Addus Q3 net service revenues up 25% yr/yr to $362.3 mln * Adjusted EPS for Q3 beats analyst expectations * Adjusted EBITDA for Q3 beats analyst expectations * Company completed Del Cielo acquisition on Oct 1, expanding Texas operations Outlook * Company anticipates positive impact from recent Texas rate increase * Addus expects continued growth in hospice care...

Overview * Gladstone Q3 operating revenue grows 3.3%, beating analyst expectations * Net income for Q3 beats analyst estimates despite decline from prior quarter * Company acquired six-facility portfolio and sold non-core property Outlook * Gladstone Commercial ( GOOD ) did not provide specific future guidance in the statement Result Drivers * PROPERTY ACQUISITIONS - Co acquired a six-facility portfolio,...

Overview * Navitas Q3 2025 revenue beats analyst expectations despite declining yr/yr * Company reports GAAP loss from operations improves compared to Q3 2024 * Navitas pivots to high-power markets, collaborating with NVIDIA on AI data centers Outlook * Navitas expects Q4 2025 net revenues of $7.0 mln, plus or minus $0.25 mln * Company anticipates Q4 2025 non-GAAP gross...